Citation Impact
Citing Papers
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
2009 Standout
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
2002
PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas.
2001
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Metal‐Ion‐Dependent Biological Properties of a Chelator‐Derived Somatostatin Analogue for Tumour Targeting
2008
Endogenous human microRNAs that suppress breast cancer metastasis
2008 StandoutNature
Tenascin-C induced signaling in cancer
2006
Octreotide Versus Octreotide Plus Interferon-Alpha in Endocrine Gastroenteropancreatic Tumors: A Randomized Trial
2005
99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives
2000
Formation and Function of the Myofibroblast during Tissue Repair
2007 Standout
Gallium-68-DOTA-albumin as a PET blood-pool marker: experimental evaluation in vivo
2005
A comparison of 111In-DOTATOC and 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours
2004
Ga-66 labeled somatostatin analogue DOTA-DPhe 1 -Tyr 3 -octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors
2002
Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities
2003
Molecular imaging with copper-64
2004
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Molecular Imaging of Cancer with Copper-64 Radiopharmaceuticals and Positron Emission Tomography (PET)
2009
114mIn, a candidate for radionuclide therapy: low-energy cyclotron production and labeling of DTPA-D-Phe-octreotide
2000
Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”
2007
Taking advantage of luminescent lanthanide ions
2005 Standout
Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy
2006
Mechanotransduction and extracellular matrix homeostasis
2014 Standout
A Triazacyclononane‐Based Bifunctional Phosphinate Ligand for the Preparation of Multimeric 68Ga Tracers for Positron Emission Tomography
2010
[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients
2001
Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET
2005
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma
2009
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Neuroendocrine tumor targeting: Study of novel gallium‐labeled somatostatin radiopeptides in a rat pancreatic tumor model
2002
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
Influence of Macrocyclic Chelators on the Targeting Properties of 68Ga-Labeled Synthetic Affibody Molecules: Comparison with 111In-Labeled Counterparts
2013
Development of an in vitro model for assessing the in vivo stability of lanthanide chelates
2001
68Ga- and 111In-labelled DOTA-RGD peptides for imaging of αvβ3 integrin expression
2008
Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?
2011
Survival and Response After Peptide Receptor Radionuclide Therapy With [90Y-DOTA0,Tyr3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors
2006
Ligand liposomes and boron neutron capture therapy
2003
Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data
2001
Synthesis of [18F]RGD-K5 by catalyzed [3+2] cycloaddition for imaging integrin αvβ3 expression in vivo
2013 StandoutNobel
Antibody therapy of cancer
2012 Standout
Aptamers as therapeutics
2010 Standout
Design considerations for tumour-targeted nanoparticles
2009 StandoutNobel
68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT
2007
DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals
2003
Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours
2004
Aptamers as targeted therapeutics: current potential and challenges
2016 Standout
Antibody-Based Vascular Tumor Targeting
2009
Magnetic nanoparticles in MR imaging and drug delivery
2008 Standout
Immunotherapy of Brain Cancers: The Past, the Present, and Future Directions
2010
Radiometallated peptides for molecular imaging and targeted therapy
2011
Strategies in the design of nanoparticles for therapeutic applications
2010 Standout
A practical guide to the construction of radiometallated bioconjugates for positron emission tomography
2011
Tumour uptake of the radiolabelled somatostatin analogue [DOTA 0 ,TYR 3 ]octreotide is dependent on the peptide amount
1999
Tenascins: regulation and putative functions during pathological stress
2003
Identification of a Glioblastoma-Associated Tenascin-C Isoform by a High Affinity Recombinant Antibody
1999 StandoutNobel
Matching chelators to radiometals for radiopharmaceuticals
2013 Standout
Tetrafluorophenolate of HBED-CC: a versatile conjugation agent for 68Ga-labeled small recombinant antibodies
2008
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
2009 Standout
Pyrene-sensitised near-IR luminescence from ytterbium and neodymium complexes
2004
Efficient bifunctional gallium-68 chelators for positron emission tomography: tris(hydroxypyridinone) ligands
2011
Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation
2004
Tumour vascular targeting
2005
68Ga‐PET: a powerful generator‐based alternative to cyclotron‐based PET radiopharmaceuticals
2008
Radiolabelling DOTA-peptides with 68Ga
2005
Gallium-68-labeled DOTA-rhenium-cyclized α-melanocyte-stimulating hormone analog for imaging of malignant melanoma
2007
Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach
2000
A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labelling
2000
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial
2010
Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides
2008
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
2015 Standout
Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce
2006 Standout
Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
2009 Standout
Sr/Y separation by supported liquid membranes based on nuclear track micro filters
2003
Complexation of Metal Ions with TRAP (1,4,7-Triazacyclononane Phosphinic Acid) Ligands and 1,4,7-Triazacyclononane-1,4,7-triacetic Acid: Phosphinate-Containing Ligands as Unique Chelators for Trivalent Gallium
2011
Structural and Dynamic Studies of Zinc, Gallium, and Cadmium Complexes of a Dicarboxylate Pendant‐Armed Cross‐Bridged Cyclen
2006
Gallium(III) Complexes of DOTA and DOTA−Monoamide: Kinetic and Thermodynamic Studies
2010
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Bifunctional Chelators for Therapeutic Lanthanide Radiopharmaceuticals
2000
Synthesis, Characterization, and X-ray Crystal Structure of In(DOTA-AA) (AA = p-Aminoanilide): A Model for 111In-Labeled DOTA-Biomolecule Conjugates
2003
111In-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-lys(8)-vasotocin: a new powerful radioligand for oxytocin receptor-expressing tumors.
2001
Radiolabeled Cyclic RGD Peptides as Integrin αvβ3-Targeted Radiotracers: Maximizing Binding Affinity via Bivalency
2009
Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model.
1999
A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases.
2004
Monoclonal Antibodies for Cancer Therapy
2012 StandoutNobel
NODAGATOC, a New Chelator-Coupled Somatostatin Analogue Labeled with [67/68Ga] and [111In] for SPECT, PET, and Targeted Therapeutic Applications of Somatostatin Receptor (hsst2) Expressing Tumors
2002
Acyclic Chelate with Ideal Properties for 68Ga PET Imaging Agent Elaboration
2010
Structural and Dynamic Studies of Zinc, Gallium, and Cadmium Complexes of a Dicarboxylate Pendant‐Armed Cross‐Bridged Cyclen
2004
Compact Cysteine-Coated CdSe(ZnCdS) Quantum Dots for in Vivo Applications
2007 StandoutNobel
Synthesis, Characterization and In Vivo Studies of Cu(II)-64-Labeled Cross-Bridged Tetraazamacrocycle-amide Complexes as Models of Peptide Conjugate Imaging Agents
2007
Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells.
2003
Synthetic Strategies Toward N‐Functionalized Cyclens
2008
The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors
2004
Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice.
2003
H4octapa: An Acyclic Chelator for 111In Radiopharmaceuticals
2012
Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
1999
Phase II Trial of Murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas
2002
Technetium and Gallium Derived Radiopharmaceuticals: Comparing and Contrasting the Chemistry of Two Important Radiometals for the Molecular Imaging Era
2010
110mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine tumors with PET.
2002
Radiometal-Labeled Agents (Non-Technetium) for Diagnostic Imaging
1999
Antibody−Dendrimer Conjugates: The Number, Not the Size of the Dendrimers, Determines the Immunoreactivity
2008
Synthesis, structure and thermal analysis of the gallium complex of 1,4,7,10-tetraazacyclo-dodecane-N,N′,N″,N‴-tetraacetic acid (DOTA)
2006
Synthesis of a DOTA−Biotin Conjugate for Radionuclide Chelation via Cu-Free Click Chemistry
2010
Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis
2008
Conjugation of DOTA Using Isolated Phenolic Active Esters: The Labeling and Biodistribution of Albumin as Blood Pool Marker
2004
Pyridine- and Phosphonate-Containing Ligands for Stable Ln Complexation. Extremely Fast Water Exchange on the GdIII Chelates
2006
Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects
2005 Standout
Advances in Copper Complexes as Anticancer Agents
2013 Standout
GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog.
2005
Guidelines for the management of thyroid cancer
2014 Standout
Synthesis and Structural Characterization of Complexes of a DO3A-Conjugated Triphenylphosphonium Cation with Diagnostically Important Metal Ions
2007
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
Tissue- and Organ-Selective Biodistribution of NIR Fluorescent Quantum Dots
2009 StandoutNobel
Polar Red‐Emitting Rhodamine Dyes with Reactive Groups: Synthesis, Photophysical Properties, and Two‐Color STED Nanoscopy Applications
2013 StandoutNobel
Radiolabeling Strategies for Tumor-Targeting Proteinaceous Drugs
2014
Recent developments in the design of bifunctional chelators for metal-based radiopharmaceuticals used in Positron Emission Tomography
2012
1,4,7-Triazacyclononane-1-succinic acid-4,7-diacetic acid (NODASA): a new bifunctional chelator for radio gallium-labelling of biomolecules
1998
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
2003
Works of E. Jermann being referenced
DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy
1997
Biodistribution of111In-labelled SCN-bz-DTPA-BC-2 MAb following loco-regional injection into glioblastomas
1997
Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy
1997
Biokinetics and dosimetry in patients administered with 111 In-DOTA-Tyr 3 -octreotide: implications for internal radiotherapy with 90 Y-DOTATOC
1999
Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas.
1999
Radiometal-Labelled Macrocyclic Chelator-Derivatised Somatostatin Analogue with Superb Tumour-Targeting Properties and Potential for Receptor-Mediated Internal Radiotherapy
1999
Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA 0 , d -Phe 1 ,Tyr 3 ]octreotide, a promising somatostatin analogue for radionuclide therapy
1997
Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study.
1999